Rare and Serious Diseases
Our top priority is saving and improving the lives of our patients. CSL's commitment to enhancing the quality of life for people with rare and serious diseases around the globe is reflected in our support of programs and activities for patients with rare plasma-protein related diseases, including bleeding disorders, primary immune deficiencies and Alpha 1 proteinase inhibitor deficiencies.
We collaborate with patient advocacy groups, both disease-specific and umbrella organizations, to promote quality medical care and services. We aim to improve and expand educational and outreach efforts. Through these partnerships, we strive to raise public awareness and to enhance appropriate public policies for rare diseases.
Saving lives and improving the quality of life for people with serious and rare conditions is what we do. Listening to our patients while continuing to introduce new innovations that address unmet medical needs or enhance current treatments is how we do it. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our patients’ needs.Visit CSL Behring
CSL Plasma, a division of CSL Behring, operates one of the world’s largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in U.S., Europe and China and employs over 12,000 people.
CSL Plasma is vertically integrated, meaning plasma collected at CSL Plasma facilities are used by CSL Behring for the sole purpose of manufacture and deliver its life-saving therapies to people in more than 100 countries.